The 'Vieillissement, cognition et maladie d’Alzheimer' (Aging, Cognition, and Alzheimer’s Disease) is an internationally recognized, multidisciplinary research program offered by the Douglas Research Centre, affiliated with McGill University. This program is dedicated to advancing the understanding of the neurobiology of healthy and unhealthy aging, with a specific focus on cognitive function and the etiology of Alzheimer's disease. It serves as a central hub for researchers seeking expertise, collaboration, and access to advanced methodologies in this critical area of mental health research. This comprehensive program leverages cutting-edge technologies and methodologies to explore the complexities of age-related disorders. Key technical capabilities include advanced biomarker monitoring, genetic stratification, and sophisticated multi-model imaging techniques that extend beyond traditional assessments like hippocampal volume measurements. The program actively collaborates with the McGill Genome Centre on novel proteomic technologies, enabling the simultaneous monitoring of over 95 proteins in blood and cerebrospinal fluid from experimental subjects. Furthermore, it investigates alternative, cost-effective biomarker assays for Alzheimer-related pathology in blood, providing viable alternatives to more invasive or expensive methods like PET imaging or lumbar punctures. The research conducted within this program has broad applications across neuroscience, gerontology, and clinical psychiatry. It is commonly used in studies aimed at identifying early markers of Alzheimer's disease, understanding disease progression, and developing new therapeutic and preventive strategies. Research areas include the manipulation of lifestyle-associated protective factors such as exercise, pharmacological control of cholesterol levels and systolic blood pressure, and diabetes management. The program's interdisciplinary and multidisciplinary scientists have secured significant joint funding from major Canadian research bodies like CIHR and FRSQ, leading to numerous joint publications in top-tier scientific journals. This collaborative environment fosters significant advancements in both basic and clinical sciences related to aging and neurodegenerative diseases. Additional features and specialized capabilities within this research program include the integral role of the StoP-AD Centre (Centre for Studies on Prevention of Alzheimer's Disease) and the PREVENT-Alzheimer program, which specifically focus on studying Alzheimer's disease in its pre-symptomatic stages and developing prevention strategies. Researchers benefit from access to the Douglas Brain Bank, which houses and manages over 3,600 human brains for research, the state-of-the-art Cerebral Imaging Centre for pre-clinical and clinical brain imaging, and the Molecular and Cellular Microscopy Platform utilizing advanced fluorescence microscopy techniques. The Neurophenotyping service platform also provides expertise in behavioral testing and data analysis, further supporting comprehensive research into the mechanisms of aging and Alzheimer's disease.